Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. B... https://franki531cdf1.wikimidpoint.com/user